SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ellwood P. Shattuck lecture - outcomes management. A technology of patient experience. N Engl J Med 1988; 318: 1549-56.
  • 2
    Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7-26.
  • 3
    Waterhouse J, Muir C, Shanmugaratnam K, Powell J. Cancer incidence in five continents. Volume IV. Lyons, France: International Agency For Research On Cancer, 1982.
  • 4
    Muir C, Waterhouse J, Mack T, et al. Cancer incidence in five continents. Volume V. Lyons, France: International Agency For Research On Cancer, 1987.
  • 5
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104: 947-53.
  • 6
    DeGroot LJ, Kaplan EL, Straus FH. Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg 1994: 18: 123-30.
  • 7
    Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75: 714-20.
  • 8
    Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19: 545-76.
  • 9
    Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102: 1088-92.
  • 10
    Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 1 (14): 1050-61.
  • 11
    DeGroot LJ, Kaplan EL, McCorinick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-24.
  • 12
    Mazzaferri El, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-28.
  • 13
    Mettlin CJ, Menck HR, Winchester DP, Murphy GP. A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program. Cancer 1997; 79: 2057-66.
  • 14
    Natarajan N, Mettlin C, Beart RW, Murphy GP. Design and analysis of national patterns of care surveys of the American College of Surgeons. Neoplasia 1985; 2: 5-10.
  • 15
    Commission on Cancer. Data acquisition manual. Chicago: Commission on Cancer of the American College of Surgeons, 1990.
  • 16
    BeahrsO, HensonDE, HutterRVP, KennedyBJ, editors. Manual for staging of cancer. 3rd edition. Philadelphia: J.B. Lippincott Co., 1988.
  • 17
    BeahrsO, HensonDE, HutterRVP, KennedyBJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: J.B. Lippincott Co., 1992.
  • 18
    ICD-O-2. International classification of disease for oncology. 2nd edition. Geneva: World Health Organization, 1990.
  • 19
    SPSS Inc. SPSS for Windows: advanced statistics [software program for personal computers]. Release 6.1. Chicago: SPSS Inc., 1994.
  • 20
    Hundahl SA, Fleming ID, Shah JP. Thyroid cancer. In: SteeleGD, JessupJM, WinchesterDP, MenckHR, MurphyGP, editors. National Cancer Data Base annual review of patient care. Atlanta: American Cancer Society, 1995: 100-12.
  • 21
    Hannequin P, Liehn JC, DeLisle MJ. Multifactorial analysis of survival in thyroid cancer: pitfalls of applying the results of published studies to another population. Cancer 1986; 58: 1749-55.
  • 22
    Shaha AR, Loree TR, Shah JP. Intermediate risk group for differentiated carcinoma of the thyroid. Surgery 1994; 116: 1036-41.
  • 23
    Gagel RF, Goepfert H, Callender DL. Changing concepts in the pathogenesis and management of thyroid carcinoma. CA Cancer J Clin 1996; 46: 261-83.
  • 24
    Jossart GH, Clark OH. Well differentiated thyroid cancer. Curr Probl Surg 1994; 31: 935-1011.
  • 25
    Clark RL, White EC, Russell WO. Total thyroidectomy for cancer of the thyroid: significance of intraglandular dissemination. Ann Surg 1959; 149: 858-66.
  • 26
    LiVoisi VA. Surgical pathology of the thyroid. Philadelphia: W.B. Saunders Co., 1990.
  • 27
    Franssila KO, Harach HR. Occult papillary carcinoma of the thyroid in children and young adults. A systemic autopsy study in Finland. Cancer 1985; 58: 715-9.
  • 28
    Fukunaga FH, Lockett LJ. Thyroid carcinoma in the Japanese in Hawaii. Arch Pathol Lab Med 1971; 92: 6-13.
  • 29
    Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997; 4: 328-33.
  • 30
    Tollefsen HR, Shah JP, Huvos AG. Papillary carcinoma of the thyroid. Am J Surg 1972; 124: 468-72.
  • 31
    Guillamondegui OM, Mikhail RA. The treatment of differentiated carcinoma of the thyroid gland. Arch Otolaryngol 1983; 109: 743-5.
  • 32
    Wanebo HJ, Andrews W, Kaiser DL. Thyroid cancer: some basic considerations. Am J Surg 1981; 142: 474-9.
  • 33
    Foster RS. Morbidity and mortality after thyroidectomy. Surg Gynecol Obstet 1978; 146: 423-9.
  • 34
    McLeod MK. Hurthle cell neoplasms of the thyroid. Otolaryngol Clin North Am 1990; 23: 441-52.
  • 35
    Block MA. Surgical treatment of medullary carcinoma of the thyroid. Otolaryngol Clin North Am 1990; 23: 453-8.
  • 36
    Lairmore TC, Wells SA. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol 1991; 7: 92-9.
  • 37
    Aldinger KA, Samaan NA, Ibanez M, Hall CS. Anaplastic carcinoma of the thyroid. A review of 84 cases. Cancer 1978; 41: 2267-75.
  • 38
    National Cancer Institute. Estimated exposures and thyroid doses received by the American people from iodine-131 in fallout following Nevada Atmospheric Nuclear Bomb tests. A report from The National Cancer Institute. Washington, DC: U. S. Department of Health and Human Services; 1997 NIH Pub. No. 97-4264.
  • 39
    Hundahl SA. Review: National Cancer Institute report on iodine-131 exposure from fallout following Nevada Atmospheric Nuclear Bomb tests. CA Cancer J Clin 1998; 48: 285-98.